Cessation of Bezafibrate in patients with chronic kidney disease improves renal function

Bezafibrate (BzF) is eliminated by renal excretion and dosage must be reduced in patients with chronic kidney disease (CKD). There is a concern that BzF causes a further deterioration in renal function in patients with CKD. This study assessed whether BzF discontinuation or dose reduction in CKD pat...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2020-11, Vol.10 (1), p.19768-19768, Article 19768
Main Authors: Zingerman, Boris, Ziv, Danny, Feder Krengel, Netta, Korzets, Asher, Matok, Ilan
Format: Article
Language:English
Subjects:
692/163/2743/2099
692/4022/1585/104
692/700/565/1436
Aged
Aged, 80 and over
Bezafibrate
Bezafibrate - pharmacokinetics
Bezafibrate - therapeutic use
Case-Control Studies
Creatine Kinase - blood
Creatinine
Creatinine - blood
Demography
Dosage
Epidermal growth factor receptors
Female
Glomerular filtration rate
Glomerular Filtration Rate - drug effects
Humanities and Social Sciences
Humans
Kidney diseases
Kidney Function Tests
Kidneys
Male
multidisciplinary
Renal function
Renal Insufficiency, Chronic - blood
Renal Insufficiency, Chronic - drug therapy
Renal Insufficiency, Chronic - metabolism
Retrospective Studies
Science
Science (multidisciplinary)
Urea
Urea - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bezafibrate (BzF) is eliminated by renal excretion and dosage must be reduced in patients with chronic kidney disease (CKD). There is a concern that BzF causes a further deterioration in renal function in patients with CKD. This study assessed whether BzF discontinuation or dose reduction in CKD patients improves renal function. 117 CKD patients treated with BzF between 2009 and 2014 were studied for demographics, comorbid conditions and laboratory variables. Data compared 2 groups: an intervention group of 64 patients where recommendations regarding BzF administration was implemented and a control group of 37 patients. Follow-up was maintained for 12 months. In the intervention group, estimated glomerular filtration rate (eGFR) increased from 38 to 42 mL/min/1.73 m 2 (p = 0.01); blood urea levels decreased from 81 to 77 mg/dL (p = 0.04). Serum creatinine decreased by more than 0.2 mg/dL in 45% of the intervention group, as compared to 19% of the control group (p 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-020-76861-1